{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T16:05:45Z","timestamp":1779206745076,"version":"3.51.4"},"reference-count":5,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Digital cognitive assessments represent an important and rapidly evolving approach to detecting cognitive impairment and Alzheimer\u2019s disease\u2013related pathology. Jannati et al. report promising findings using a multimodal digital clock and recall assessment to identify cognitive impairment and amyloid positivity. While this contribution is welcomed, several comparative statements regarding Cognivue\n                    <jats:sup>\u00ae<\/jats:sup>\n                    rely on historical regulatory data and do not reflect the contemporaneous peer-reviewed evidence base available at the time of manuscript preparation. This Matters Arising article clarifies the limitations of cross-study performance comparisons, addresses selective citation of a single early Cognivue publication, and summarizes subsequent peer-reviewed findings demonstrating Cognivue\u2019s psychometric validity, biomarker associations, and generalizability across diverse populations. These considerations highlight the importance of harmonized, contemporaneous comparisons when asserting relative performance among digital cognitive assessment tools.\n                  <\/jats:p>","DOI":"10.1186\/s13195-026-02057-w","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T15:06:08Z","timestamp":1779203168000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clarifying comparative claims in digital cognitive assessment: a matters arising on multimodal detection of cognitive impairment and amyloid positivity"],"prefix":"10.1186","volume":"18","author":[{"given":"Paul W.","family":"Estes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,5,19]]},"reference":[{"key":"2057_CR1","unstructured":"U.S. Food and Drug Administration. Summary of Safety and Effectiveness Data (SSED): Cognivue 510(k) de novo clearance. 2013. https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfpmn\/denovo.cfm?id=DEN130033."},{"key":"2057_CR2","doi-asserted-by":"publisher","first-page":"24519","DOI":"10.1038\/s41598-024-75304-5","volume":"14","author":"JE Galvin","year":"2024","unstructured":"Galvin JE, Kleiman MJ, Estes PW, et al. Cognivue Clarity characterizes mild cognitive impairment and Alzheimer\u2019s disease in biomarker-confirmed cohorts in the Bio-Hermes Study. Sci Rep. 2024;14:24519. https:\/\/doi.org\/10.1038\/s41598-024-75304-5.","journal-title":"Sci Rep"},{"key":"2057_CR3","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1177\/13872877251314117","volume":"104","author":"JE Galvin","year":"2025","unstructured":"Galvin JE, Kleiman MJ, Harris HM, et al. Cognivue Clarity\u00ae characterizes amyloid status and preclinical Alzheimer\u2019s disease in biomarker-confirmed cohorts in the Bio-Hermes Study. J Alzheimer\u2019s Disease. 2025;104:83\u201394.","journal-title":"J Alzheimer\u2019s Disease"},{"key":"2057_CR4","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1007\/s40120-025-00741-x","volume":"14","author":"JE Galvin","year":"2025","unstructured":"Galvin JE, Kleiman MJ, Harris HM, Estes PW. The Cognivue Amyloid Risk Measure (CARM): A novel method to predict the presence of amyloid with Cognivue Clarity. Neurol Therapy. 2025;14:865\u201380.","journal-title":"Neurol Therapy"},{"issue":"2","key":"2057_CR5","doi-asserted-by":"publisher","first-page":"509","DOI":"10.3233\/JAD-240331","volume":"100","author":"JE Galvin","year":"2024","unstructured":"Galvin JE, Chang LC, Estes PW, Harris HM, Fung E. Cognitive Assessment with Cognivue Clarity\u00ae: Psychometric Properties and Enhanced Normative Ranges in a Diverse Population. J Alzheimer\u2019s Disease. 2024;100(2):509\u201323.","journal-title":"J Alzheimer\u2019s Disease"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-026-02057-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-026-02057-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-026-02057-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T15:06:09Z","timestamp":1779203169000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13195-026-02057-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,19]]},"references-count":5,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2057"],"URL":"https:\/\/doi.org\/10.1186\/s13195-026-02057-w","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,19]]},"assertion":[{"value":"20 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Paul W. Estes is an employee of Cognivue, Inc.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"114"}}